Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.30M | -209.80K | -408.70K | -736.00K | 115.30K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 14.80K | 64.30K | 38.00K | 301.90K | -251.80K |
| Total Other Non-Cash Items | 3.02M | -92.00K | 19.30K | 415.60K | -286.30K |
| Change in Net Operating Assets | 128.40K | -24.30K | 120.00K | -354.20K | 173.90K |
| Cash from Operations | -143.20K | -261.80K | -231.40K | -372.60K | -248.90K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 220.00K | 145.00K | 250.00K | 300.00K | 420.00K |
| Total Debt Repaid | -- | -- | -- | 0.00 | -35.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -25.00K | -50.00K |
| Cash from Financing | 220.00K | 145.00K | 250.00K | 275.00K | 335.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.80K | -116.80K | 18.60K | -97.60K | 86.20K |